Truist Financial Corp Lowers Stake in Emergent Biosolutions Inc. $EBS

Truist Financial Corp lowered its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 25.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 219,452 shares of the biopharmaceutical company’s stock after selling 74,342 shares during the period. Truist Financial Corp’s holdings in Emergent Biosolutions were worth $2,712,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Legal & General Group Plc purchased a new position in shares of Emergent Biosolutions during the 2nd quarter worth approximately $31,000. Torren Management LLC purchased a new position in Emergent Biosolutions in the 4th quarter valued at approximately $37,000. Raymond James Financial Inc. purchased a new position in Emergent Biosolutions in the 2nd quarter valued at approximately $53,000. Farther Finance Advisors LLC boosted its position in Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 4,827 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in Emergent Biosolutions by 133.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,942 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 6,246 shares during the period. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on EBS shares. Weiss Ratings cut shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday. Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, HC Wainwright decreased their price target on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, March 9th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Emergent Biosolutions currently has an average rating of “Hold” and an average price target of $12.00.

Insider Activity at Emergent Biosolutions

In other news, Director Sujata Tyagi Dayal sold 13,761 shares of Emergent Biosolutions stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total value of $115,592.40. Following the sale, the director owned 100,563 shares of the company’s stock, valued at $844,729.20. The trade was a 12.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Katkin sold 15,481 shares of Emergent Biosolutions stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $8.28, for a total transaction of $128,182.68. Following the completion of the sale, the director directly owned 96,294 shares in the company, valued at approximately $797,314.32. The trade was a 13.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,925 shares of company stock valued at $518,312 over the last quarter. 6.00% of the stock is owned by insiders.

Emergent Biosolutions Price Performance

Shares of NYSE:EBS opened at $8.51 on Wednesday. The company’s fifty day moving average price is $8.36 and its 200 day moving average price is $10.29. Emergent Biosolutions Inc. has a 12 month low of $5.30 and a 12 month high of $14.06. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08. The firm has a market capitalization of $439.23 million, a P/E ratio of -30.38 and a beta of 2.33.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The firm had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.